Jackie Syrop


Study Finds ABP 215 and Bevacizumab Demonstrate PK Similarity in Japanese Men

November 18, 2018

The researchers say that their data were consistent with the pharmacokinetic equivalence previously demonstrated in a single-dose PK study that included 202 healthy adult men in the United States and European Union, and thus add to the evidence of ABP-215 as a high-quality biosimilar to bevacizumab for use in Japan.

Research Underscores Rituximab's Utility in Treating MS

November 15, 2018

Rituximab is frequently used off-label as a treatment for relapsing-remitting multiple sclerosis (MS) because it induces the depletion of circulating B-cell and T-cell lymphocytes and targets CD20 protein in B cells that are responsible for the production of antibodies.

Does Biosimilar Infliximab Have a Role After Secondary Loss of Response to Its Reference?

November 15, 2018

Results of a small Greek observational study suggest that biosimilar infliximab may be an effective alternative for the treatment of patients with inflammatory bowel disease (IBD) who have active disease and experienced a loss of response to innovator infliximab (Remicade).